Since the discovery of induced pluripotent stem cell (iPSC) technology 18 years ago, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. [Read more…]
iPSCs are Transforming Drug Discovery, Toxicity Testing, Disease Modeling, and Beyond
Induced pluripotent stem cells (iPS cells or iPSCs) are laboratory-made pluripotent stem cells that are produced using adult cells. They are derived from somatic cells by reprogramming artificially and turning on the expression of specific pluripotency genes. The reprogramming is achieved using different techniques with varying efficiencies. The iPSC technology was first discovered in 2006 by Shinya Yamanaka’s lab in Kyoto, Japan. He and his team introduced four specific genes encoding transcription factors and converted adult cells into pluripotent stem cells. [Read more…]
Induced Pluripotent Stem Cell (iPS Cell) Applications in 2026
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]
CIRM’s iPSC Repository Closes, Marking the End of a Landmark Resource for Stem Cell Research
Sadly, in July 2025, the California Institute for Regenerative Medicine (CIRM) officially closed its iPSC Repository, marking the end of one of the world’s most comprehensive publicly funded collections of human induced pluripotent stem cell (hiPSC) lines. With the repository’s closure, these cells are no longer available for purchase or distribution, a development that has drawn wide attention and sadness across the global stem cell community. [Read more…]
Qihan Biotech’s QN-139b becomes First iPSC-derived CAR NK therapy for Autoimmune Disease
A new chapter is beginning for iPSCs: Qihan Biotech, a leading innovator in cell engineering, has reported the first clinical use of an induced pluripotent stem cell (iPSC)-derived CAR natural killer (NK) therapy in an autoimmune disease. The product, known as QN-139b, was administered to a patient with refractory systemic sclerosis (SSc), marking the first time an iPSC-derived CAR immune therapy has been used beyond oncology. [Read more…]
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 78
- Next Page »